"At the Laurel Amtower Cancer Institute at Sharp Memorial, we battle cancer the best ways we know how — with cutting-edge treatments, advanced technologies, groundbreaking clinical research and complete dedication to your wellness and vitality. When it comes to cancer treatment at Sharp, we explore all possibilities. A leader in clinical oncology research, we offer clinical trials where new cancer treatments are discovered and put to use with positive outcomes. Our nationally accredited cancer services offer you the best of care every step of the way, from genetic counseling to diagnostic imaging to radiation therapy."

During the past decade, Sharp Clinical Oncology Research conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 17 clinical trials were completed, i.e. on average, 425% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 6 clinical trials were completed. i.e. 600% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Sharp Clinical Oncology Research" #1 sponsor was "Bristol-Myers Squibb" with 13 trials, followed by "Agennix" with 2 trials sponsored, "Dendreon" with 2 trials sponsored, "Novartis Pharmaceuticals" with 2 trials sponsored and "Proacta, Incorporated" with 2 trials sponsored. Other sponsors include 10 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Sharp Clinical Oncology Research" #1 collaborator was "AbbVie" with 3 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Daiichi Sankyo Co., Ltd." with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator and "Hoffmann-La Roche" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Sharp Clinical Oncology Research" are "Breast Cancer" (7 trials), "Non-Small Cell Lung Cancer" (3 trials), "Prostate Cancer" (3 trials), "Adenocarcinoma" (2 trials) and "Hepatocellular Carcinoma" (2 trials). Many other conditions were trialed in "Sharp Clinical Oncology Research" in a lesser frequency.

Most popular intervention types in "Sharp Clinical Oncology Research" are "Drug" (32 trials), "Biological" (7 trials), "Other" (2 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Brivanib" (3 trials), "Paclitaxel" (3 trials), "Bevacizumab" (2 trials) and "Carboplatin" (2 trials). Other intervention names were less common.

The vast majority of trials in "Sharp Clinical Oncology Research" are 22 trials for "All" genders, 7 trials for "Female" genders and 6 trials for "Male" genders.

Currently, there are NaN active trials in "Sharp Clinical Oncology Research". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 27 completed trials in Sharp Clinical Oncology Research, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Sharp Clinical Oncology Research, 2 "Phase 1" clinical trials were conducted, 17 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".